AUTHOR=Liu Zhen z., Liu Tong , Zhang Zhen t., Fan Yu r.

TITLE=Bacillus coagulans regulates gut microbiota and ameliorates the alcoholic-associated liver disease in mice

JOURNAL=Frontiers in Microbiology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1337185

DOI=10.3389/fmicb.2024.1337185

ISSN=1664-302X

ABSTRACT=<sec><title>Introduction</title><p>Alcoholic-associated liver diseases (ALD) are now widespread issues worldwide. Alcoholic-induced chronic dysbiosis of the gut microbiota is one of the factors in the pathophysiology of ALD.</p></sec><sec><title>Methods</title><p>In this work, we employed a chronic-binge ethanol feeding mice model, as described in a previous report.</p></sec><sec><title>Results</title><p>Our findings demonstrate that hepatic inflammatory injury damage and accumulation of fat can be effectively reduced in mice with ALD by altering the gut microbiota utilizing <italic>Bacillus coagulans</italic>. Treatment with <italic>B. coagulans</italic> significantly modulates the levels of TNF-α, IL-1β, and IL-22 cytokines while maintaining tight junction proteins and mucin protein expressions to support intestinal barrier function restoration. Treatment with <italic>B. coagulans</italic> also alters the composition of the gut microbiota and increases the production of short-chain fatty acids (SCFAs).</p></sec><sec><title>Discussion</title><p>This is mostly due to <italic>B. coagulans</italic> promotes the growth of bacteria that produce SCFAs, such as <italic>Ruminococcus</italic> species and <italic>Akkermansia</italic>, while inhibiting the growth of pathogenic bacteria like <italic>Escherichia Shigella</italic>. Moreover, treatment with <italic>B. coagulans</italic> causes levels of <italic>2-Ketobutyric acid</italic>, <italic>ketoleucine</italic>, and <italic>indoleacetic acid</italic> increase while <italic>homovanillic acid</italic> and <italic>3’-O-Methylguanosine</italic> metabolites decrease significantly. This study facilitates the development of therapeutic and preventive strategies for ALD using lactic acid bacteria.</p></sec>